Revista Iberoamericana De Micologia最新文献_第8页

Anfotericina B liposomal en el tratamiento de la leishmaniasis visceral 脂质体两性霉素B治疗内脏利什曼病

IF 1.9 4区生物学

Revista Iberoamericana De Micologia Pub Date : 2021-04-01 DOI: 10.1016/j.riam.2021.04.002

Begoña Monge-Maillo, Rogelio López-Vélez

引用次数: 3

Mucormicosis: perspectiva de manejo actual y de futuro 毛霉病:当前和未来的管理展望

IF 1.9 4区生物学

Revista Iberoamericana De Micologia Pub Date : 2021-04-01 DOI: 10.1016/j.riam.2021.04.003

María Teresa Martín Gómez , Miguel Salavert Lletí

{"title":"Mucormicosis: perspectiva de manejo actual y de futuro","authors":"María Teresa Martín Gómez , Miguel Salavert Lletí","doi":"10.1016/j.riam.2021.04.003","DOIUrl":"https://doi.org/10.1016/j.riam.2021.04.003","url":null,"abstract":"<div><p>Infections caused by mucorales, with an increasing incidence after candidiasis and aspergillosis, are characterized by the fast angioinvasion of blood vessels and invasion of neighboring organs or structures. Mucorales most commonly cause rhinocerebral, pulmonary, cutaneous, digestive or disseminated infections, and their spread is favored by certain underlying diseases (diabetes, kidney failure) and risk factors (neutropenia, immunosuppression, iron overload). These infections have a high mortality rate, over 40% in many series, and the key to their cure depends on both an early diagnosis and an antifungal treatment, associated in most cases with extensive surgical debridement and other adjunctive therapies. Currently, there are international guidelines, not only local ones, for the management of mucormycosis, in which it is considered by consensus and with a strong recommendation that first-line treatment with high-dose liposomal amphotericin B is the best choice. The combined antifungal treatment of polyene agents with triazoles or candins remains in open debate.</p></div>","PeriodicalId":21291,"journal":{"name":"Revista Iberoamericana De Micologia","volume":"38 2","pages":"Pages 91-100"},"PeriodicalIF":1.9,"publicationDate":"2021-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/j.riam.2021.04.003","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"91750161","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"生物学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 6

Anfotericina B liposomal: farmacología clínica, farmacocinética y farmacodinamia 脂质体两性霉素B:临床药理学、药代动力学和药效学

IF 1.9 4区生物学

Revista Iberoamericana De Micologia Pub Date : 2021-04-01 DOI: 10.1016/j.riam.2021.02.004

José Ramón Azanza Perea

引用次数: 1

Anfotericina B liposomal: treinta años de una herramienta muy eficaz para el tratamiento de las micosis invasoras 脂质体两性霉素B:三十年来治疗侵袭性真菌病的非常有效的工具

IF 1.9 4区生物学

Revista Iberoamericana De Micologia Pub Date : 2021-04-01 DOI: 10.1016/j.riam.2021.04.007

Javier Pemán , Guillermo Quindós

引用次数: 1

Relevancia de la anfotericina B liposomal en el tratamiento de las infecciones fúngicas invasoras en pacientes oncohematológicos 脂质体两性霉素B在肿瘤血液学患者侵袭性真菌感染治疗中的相关性

IF 1.9 4区生物学

Revista Iberoamericana De Micologia Pub Date : 2021-04-01 DOI: 10.1016/j.riam.2021.03.001

Carolina García-Vidal , Lourdes Vázquez , Isidro Jarque

{"title":"Relevancia de la anfotericina B liposomal en el tratamiento de las infecciones fúngicas invasoras en pacientes oncohematológicos","authors":"Carolina García-Vidal , Lourdes Vázquez , Isidro Jarque","doi":"10.1016/j.riam.2021.03.001","DOIUrl":"https://doi.org/10.1016/j.riam.2021.03.001","url":null,"abstract":"<div><p>Liposomal amphotericin B (L-AmB) has been a key cornerstone for the management of invasive fungal infections (IFI) caused by a wide array of molds and yeasts during the last three decades. Multiple studies performed over this period have generated a large body of evidence on its efficacy and safety, becoming the main antifungal agent in the management of IFI in patients with hematologic malignancies in several not mutually exclusive clinical settings. First, L-AmB is the most commonly used antifungal agent in patients undergoing intensive chemotherapy for acute leukemia and high-risk myelodysplastic syndrome, as well as in hematopoietic stem cell transplant recipients. Additionally, due to the administration of newer targeted therapies (such as monoclonal antibodies or small molecule inhibitors), opportunistic mold infections are increasingly being reported in patients with hematologic malignancies usually considered low-risk for IFI. These agents usually have a high drug-drug interaction potential, being triazoles, commonly used for antifungal prophylaxis, included. Finally, patients developing breakthrough IFI because of either subtherapeutic concentrations of antifungal prophylactic drugs in blood or selection of resistant strains, require broad spectrum antifungal therapy, usually with an antifungal of a different class. In both situations, L-AmB remains as the best option for early antifungal therapy.</p></div>","PeriodicalId":21291,"journal":{"name":"Revista Iberoamericana De Micologia","volume":"38 2","pages":"Pages 61-67"},"PeriodicalIF":1.9,"publicationDate":"2021-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/j.riam.2021.03.001","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"91621749","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"生物学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 4

La infección fúngica en el paciente pediátrico inmunodeprimido 小儿免疫功能低下患者的真菌感染

IF 1.9 4区生物学

Revista Iberoamericana De Micologia Pub Date : 2021-04-01 DOI: 10.1016/j.riam.2021.04.005

Marta González-Vicent , José Tomás Ramos-Amador

{"title":"La infección fúngica en el paciente pediátrico inmunodeprimido","authors":"Marta González-Vicent , José Tomás Ramos-Amador","doi":"10.1016/j.riam.2021.04.005","DOIUrl":"https://doi.org/10.1016/j.riam.2021.04.005","url":null,"abstract":"<div><p>In recent years, immunodeficiency condition has experienced a rise among children, who are at risk of invasive fungal infections (IFI) due to their health condition. Cancer, non-malignant hematological diseases, as primary immunodeficiencies, hematopoietic stem cell transplantation (HSCT), extreme prematurity, or critically ill condition in Pediatric Intensive Care Unit (PICU) are some immunosuppressive situations in children. The use of oncologic therapies, including immunotherapy and monoclonal antibodies, for the treatment of the aforementioned health conditions has led to an increase in morbidity and mortality rates of IFI in children.</p><p>The underlying diseases and their management, comorbidities, the diagnostic tests used (both molecular and imaging), as well as the treatment used can be significantly different between adult patients and children admitted to PICU or with cancer. In pediatrics, the treatment of IFI is based primarily on pharmacokinetic studies performed in adults. In higher risk patients prophylaxis should be considered and, in the case of an IFI diagnosis, an antifungal treatment should be administered as early as possible, supported by the reversion of the immune dysfunction and surgery when appropriate.</p></div>","PeriodicalId":21291,"journal":{"name":"Revista Iberoamericana De Micologia","volume":"38 2","pages":"Pages 75-83"},"PeriodicalIF":1.9,"publicationDate":"2021-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/j.riam.2021.04.005","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"91621747","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"生物学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 2

Tratamiento antifúngico individualizado en el paciente crítico con infección fúngica invasora 侵袭性真菌感染危重患者个体化抗真菌治疗

IF 1.9 4区生物学

Revista Iberoamericana De Micologia Pub Date : 2021-04-01 DOI: 10.1016/j.riam.2021.04.006

Rafael Zaragoza , Emilio Maseda , Javier Pemán

{"title":"Tratamiento antifúngico individualizado en el paciente crítico con infección fúngica invasora","authors":"Rafael Zaragoza , Emilio Maseda , Javier Pemán","doi":"10.1016/j.riam.2021.04.006","DOIUrl":"https://doi.org/10.1016/j.riam.2021.04.006","url":null,"abstract":"<div><p>Invasive candidiasis (IC) is the most common invasive fungal infection (IFI) affecting critically ill patients, followed by invasive pulmonary aspergillosis (IPA). International guidelines provide different recommendations for a first-line antifungal therapy and, in most of them, echinocandins are considered the first-line treatment for IC, and triazoles are so for the treatment of IPA. However, liposomal amphotericinB (L-AmB) is still considered a second-line therapy for both clinical entities. Although in the last decade the management of IFI has improved, several controversies persist. The antifungal drugs currently available may have a suboptimal activity, or be wrongly used in certain IFI involving critically ill patients. The aim of this review is to analyze when to provide individualized antifungal therapy to critically ill patients suffering from IFI, emphasizing the role of L-AmB. Drug-drug interactions, the clinical status, infectious foci (peritoneal candidiasis is discussed), the fungal species involved, and the need of monitoring the concentration of the antifungal drug in the patient are considered.</p></div>","PeriodicalId":21291,"journal":{"name":"Revista Iberoamericana De Micologia","volume":"38 2","pages":"Pages 68-74"},"PeriodicalIF":1.9,"publicationDate":"2021-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/j.riam.2021.04.006","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"91621748","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"生物学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 4

Evolución de la infección fúngica invasora en los últimos 30 años 过去30年侵袭性真菌感染的演变

IF 1.9 4区生物学

Revista Iberoamericana De Micologia Pub Date : 2021-04-01 DOI: 10.1016/j.riam.2021.03.003

José Tiago Silva , Isabel Ruiz-Camps , José María Aguado

引用次数: 2

Antifúngicos de uso sistémico 全身使用的抗真菌药物

IF 1.9 4区生物学

Revista Iberoamericana De Micologia Pub Date : 2021-04-01 DOI: 10.1016/j.riam.2021.04.004

Inmaculada Quiles-Melero, Julio García-Rodríguez

{"title":"Antifúngicos de uso sistémico","authors":"Inmaculada Quiles-Melero, Julio García-Rodríguez","doi":"10.1016/j.riam.2021.04.004","DOIUrl":"10.1016/j.riam.2021.04.004","url":null,"abstract":"<div><p>Las infecciones fúngicas invasivas han aumentado en las últimas décadas y las opciones terapéuticas para combatirlas son limitadas. Los agentes antifúngicos empleados son útiles y tienen óptima actividad <em>in vitro</em>, pero pierden eficacia debido al desarrollo de resistencias por parte de los hongos. El incremento de especies con resistencia primaria o secundaria a algunos fármacos antifúngicos ha generado la necesidad de desarrollar nuevas formulaciones o recurrir a alternativas como la combinación de fármacos. En este artículo se revisará el espectro de actividad de las principales familias de antifúngicos, polienos, azoles, equinocandinas, 5-fluorocitosina y nuevos fármacos antifúngicos, así como los mecanismos de resistencia descritos contra los mismos.</p></div><div><p>Invasive fungal infections have increased over the last decades and the therapeutic choices to treat them are limited. The antifungal agents currently available are useful and have optimal in vitro activity; however, their activity can be lowered due to the development of fungal resistance. The increase in primary or secondary resistance to some antifungal drugs has led to the search of alternatives such as the combination of drugs or the development of new antifungals. In this paper, the activity of the main families of antifungal drugs, polyenes, azoles, echinocandins, 5-fluorocytosine and other new antifungal drugs, are reviewed. The main resistance mechanisms developed by fungi are also described.</p></div>","PeriodicalId":21291,"journal":{"name":"Revista Iberoamericana De Micologia","volume":"38 2","pages":"Pages 42-46"},"PeriodicalIF":1.9,"publicationDate":"2021-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/j.riam.2021.04.004","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39209636","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"生物学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 3

Seguridad clínica de la anfotericina B liposomal 脂质体两性霉素B的临床安全性

IF 1.9 4区生物学

Revista Iberoamericana De Micologia Pub Date : 2021-04-01 DOI: 10.1016/j.riam.2021.02.001

Borja Suberviola

引用次数: 3